A pack of gummy bears may have lifted your spirits as a kid, but these days, some gummies are claiming to lift a lot more.

A recent scientific review highlights increasing evidence that cannabidiol (CBD) , a compound found in cannabis, has antidepressant effects on ...

The contents of cannabis plants are both psychoactive and nutritious. Today, extracts from the cannabis plant are ingredients ...

Cannabidiol (CBD) is safe and may reduce anxiety levels two to four hours after ingestion, according to a study.

Cannabidiol is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Schizophrenia.

Cannabidiol is under clinical development by Ananda Scientific and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 73% phase transition success rate (PTSR) ...

Holdings has entered into a new exclusive U.S. distribution agreement with Green Gruff USA. Grenn Gruff offers a ...

Medical Marijuana, Inc. (OTCMKTS:MJNA – Get Free Report)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as ...

However, a new study examines whether cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant, could be a promising solution for alleviating scan-related anxiety.

The global cannabidiol oil market size was US$ 3.57 billion in 2021. The global cannabidiol oil market is forecast to grow to US$ 16.3 billion by 2030 by registering a compound annual growth rate ...

Dr. Raphael Mechoulam’s pioneering research in the 1960s on THC and CBD revolutionized cannabis medicine, leading to ...

(Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced ...